Case Report: Case report: Macrophage activation syndrome due to multifocal tuberculosis in an immunocompromised patient

Introduction

Macrophage Activation Syndrome (MAS) is a rare but life-threatening disease characterised by excessive activation and proliferation of macrophages and T lymphocytes, leading to a cytokine storm and multi-organ dysfunction.¹ While MAS is most commonly associated with rheumatic diseases, mainly systemic juvenile idiopathic arthritis and adult-onset Still’s disease, it can also be triggered by infections, malignancies, and certain medications.² However, it is rarely reported as a complication of tuberculosis, especially in immunocompromised patients. The clinical presentation of MAS is generally brutal, associating persistent fever with bi or pancytopenia. The diagnosis of MAS can be challenging, as its clinical and laboratory features may overlap with those of the underlying disease or infection.³ We present a case of a 26-year-old woman treated with azathioprine for her Crohn’s disease complicated with multifocal tuberculosis and MAS.

Case presentation

A 26-year-old- woman was referred to our hospital with abdominal pain for five days, fatigue, and fever (39°C). Her medical history included Crohn’s disease in 2018 with inflammation located in the terminal ileum and was taking azathioprine. The patient declared no exposure history to active tuberculosis in the past. Her heart rate was 121 beats per minute, blood pressure 110/77 mmHg, respiratory rate 25 breaths per minute, and temperature 39 °C. The patient had splenomegaly without hepatomegaly or adenopathy. Shifting dullness and a positive fluid wave test were found. No other signs were reported on physical examination. A chest X-ray was performed, showing bilateral pleural effusion compatible with tuberculosis. An abdominal CT scan was conducted, revealing the presence of both pleural effusion and a significant volume of ascites. High axial sections through the thoracic base showed bilateral pleural and pericardial effusion ( Figure 1).

Figure 1. Axial contrast-enhanced CT scan of the chest shows bilateral low abundance pleural effusion (green arrows) and low abundance pericardial effusion (red arrows).

Axial sections taken at portal time after injection of contrast agent showed abundant intra-peritoneal effusion ( Figure 2).

Figure 2. Axial contrast-enhanced abdominal CT scan after contrast injection showing abundant peritoneal effusion (green arrows).

A complete blood count showed normochromic normocytic anaemia, neutropenia, lymphopenia, and thrombocytopenia ( Table 1).

The patient had hyperferritinemia (1050 ng/mL), and the Fibrinogen level was at 1.5 g/l. Mild liver cholestasis was noticed (gamma-glutamyl transpeptidase (GGT) at 52 UI/L; alkaline phosphatase (ALP) at 184 UI/L). The triglyceride level was normal (0.8 mmol/L) and the electrolyte test showed hyponatremia (125 mmol/L). The low serum Ascites Albumin Gradient (SAAG) (<1.1g/dL) suggested that the ascitic fluid is an exudate. Fluid’s direct microscopic examination revealed no tuberculosis bacilli and the acid-fast stain was negative. No renal function abnormality was found. Viral serology HIV, HSV, HBV, HCV, EBV, and CMV were negative. The febrile cytopenia associated with the splenomegaly led to a bone marrow aspirate; an Xpert MTB/RIF PCR was performed and turned out positive. Rifampicin resistance was not detected. The bone marrow aspirate smear showed a reactional plasmocytosis and multiple hemophagocytosis images ( Figure 3).

Figure 3. Bone marrow aspirate smear colored with MGG staining displays features of haemophagocytosis with erythroids engulfed by macrophages (Black arrows).

Bone Marrow Biopsy was not performed. The patient was prescribed a daily oral therapy for tuberculosis, which included isoniazid, rifampicin, pyrazinamide, and ethambutol hydrochloride, and showed good progress. MAS was retained, due to clinical and biological criteria, and given the clinical course, we retained the diagnosis of multifocal tuberculosis complicated by MAS in an immunocompromised patient.

Discussion

Tuberculosis (TB) remains a significant cause of death globally. According to WHO, there were approximately 10.6 million new TB cases in 2021.⁴ TB is endemic in Tunisia, with an estimated incidence of 22.46/100,000 inhabitants in 2021.⁵

It is widely recognized that immunosuppressive therapy elevates the risk of tuberculosis, particularly in endemic regions like Tunisia.⁶ A study by Fortes et al. assessed 301 patients with inflammatory bowel disease (IBD) and found that azathioprine treatment increased the risk of developing active tuberculosis by 6.87 times compared to patients who were not receiving this medication.⁷ MAS is a serious medical condition that can be triggered by infectious agents, particularly certain viruses and mycobacteria. The majority of cases involving tuberculosis complicated by MAS occur in individuals who are immunocompromised.⁸ The disease presents significant challenges and is often associated with a poor prognosis. However, it is essential to approach this matter with a focus on early diagnosis and targeted treatment options, which can lead to improved outcomes and better management of the condition. In our case, MAS was due to multifocal tuberculosis, which involves multiple systems with associated symptoms, making the diagnosis challenging.

Multifocal tuberculosis is characterised by large multifocal tuberculosis areas in the same or different adjacent or distant organs; in our case, the organs concerned were the lungs, the digestive system, and the hematopoietic organs.⁹ The prognosis is severe, with a mortality rate of 16 to 25%, depending on the author.^10,11

Sporadic cases of multifocal tuberculosis have been reported; most of them presented with anaemia, leucopenia, and/or thrombocytopenia. In our case, the patient had pancytopenia.

MAS is an acute, sometimes fatal complication of multifocal tuberculosis. The clinical presentation is usually non-specific and can be misleading. MAS is a condition associated with hemophagocytic lymphohistiocytosis (HLH), which is categorized into primary and secondary HLH. Primary HLH is a genetic disorder, while secondary HLH arises from other conditions, such as cancers, autoimmune disorders, and infections like tuberculosis, as seen in this instance. EBV is the most prevalent infectious cause, but MAS can also be related to various infections, including viral (HIV, CMV), bacterial (Salmonella typhi), and parasitic (Leishmania sp., Toxoplasma gondii) origins.¹²

There is a set of clinical and biological criteria to define a MAS, but according to the literature, some remain more important than others. The most used criteria were Hepatosplenomegaly, fever, cytopenia, hypofibrinogenemia, hyperferritinemia, hypertriglyceridemia, hemophagocytosis, and hepatopathy. Six out of all the criteria cited below ( Table 2) were found in our patient.¹³

A study examined 37 documented instances of tuberculosis linked to MAS, revealing that half of the patients were immunocompromised (due to renal transplants, cancer, or HIV). The clinical symptoms remained consistent (such as fever and hepatosplenomegaly). In 80% of the cases, it was a disseminated tuberculosis.¹⁵

In most bone marrow aspirations, cellularity appears quite normal, and hemophagocytic histiocytes typically account for 2 to 75% of total nucleated cells. The mortality rate associated with MAS and tuberculosis reaches 50%, rising to 100% for those who do not receive any antituberculous treatment.¹⁶

Conclusion

In conclusion, we would like to present a rare case of MAS triggered by multifocal tuberculosis in a Crohn’s disease patient receiving immunosuppressive therapy. MAS is a severe complication that necessitates prompt diagnosis and management. Our case underscores the significance of considering atypical infectious symptoms in immunocompromised patients and promptly suspecting tuberculosis, particularly in patients exhibiting signs of MAS. Timely diagnosis and initiating antitubercular therapy are imperative for enhancing outcomes and averting complications.

Ethical consideration

Ethical approval was not required.

Consent statement to Publish

Written informed consent was obtained from the patient upon admission, permitting the use of their de-identified data for research and publication purposes. All identifying information has been removed to ensure the patient’s confidentiality following ethical guidelines.